Andrea Antinori to Adult
This is a "connection" page, showing publications Andrea Antinori has written about Adult.
Connection Strength
0.164
-
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review. J Neurol. 2021 Nov; 268(11):3947-3960.
Score: 0.008
-
Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Mov Disord. 2017 Dec; 32(12):1780-1783.
Score: 0.006
-
Hepatic Failure in COVID-19: Is Iron Overload the Dangerous Trigger? Cells. 2021 05 04; 10(5).
Score: 0.004
-
SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021 04 10; 13(4).
Score: 0.004
-
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021 Apr; 105:532-539.
Score: 0.004
-
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020 11 09; 222(11):1807-1815.
Score: 0.004
-
Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses. 2020 10 20; 12(10).
Score: 0.004
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.004
-
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 10 30; 30(11):1899-1913.
Score: 0.004
-
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ. 2020 11; 27(11):3196-3207.
Score: 0.004
-
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019 11 01; 74(11):3295-3304.
Score: 0.004
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.003
-
Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. Front Immunol. 2019; 10:1886.
Score: 0.003
-
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
Score: 0.003
-
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? AIDS. 2019 03 15; 33(4):759-762.
Score: 0.003
-
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019 Apr; 53(4):515-519.
Score: 0.003
-
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 12 01; 73(12):3460-3470.
Score: 0.003
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.003
-
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. HIV Clin Trials. 2018 08; 19(4):158-162.
Score: 0.003
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 01 12; 393(10167):143-155.
Score: 0.003
-
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. Sci Rep. 2018 10 24; 8(1):15739.
Score: 0.003
-
Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. AIDS Res Hum Retroviruses. 2018 11; 34(11):907-908.
Score: 0.003
-
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018 07 17; 32(11):1431-1442.
Score: 0.003
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.003
-
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
Score: 0.003
-
Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects. Immunol Lett. 2018 06; 198:33-43.
Score: 0.003
-
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018 07; 104:61-64.
Score: 0.003
-
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
Score: 0.003
-
IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. Cytokine. 2018 03; 103:34-37.
Score: 0.003
-
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. Antivir Ther. 2018; 23(2):139-148.
Score: 0.003
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.003
-
Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):417-422.
Score: 0.003
-
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care STDS. 2017 Dec; 31(12):487-494.
Score: 0.003
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.003
-
Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. J Acquir Immune Defic Syndr. 2017 11 01; 76(3):e74-e83.
Score: 0.003
-
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017; 12(10):e0186549.
Score: 0.003
-
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017; 12(10):e0186638.
Score: 0.003
-
Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. PLoS One. 2017; 12(8):e0183846.
Score: 0.003
-
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):465-471.
Score: 0.003
-
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clin Trials. 2017 07; 18(4):141-148.
Score: 0.003
-
HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):338-344.
Score: 0.003
-
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
Score: 0.003
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.003
-
Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. J Acquir Immune Defic Syndr. 2017 04 15; 74(5):575-582.
Score: 0.003
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.003
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.003
-
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
Score: 0.003
-
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar; 2(3):e98-106.
Score: 0.003
-
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002 Dec 9-23; 162(22):2621-8.
Score: 0.001